LLY vs. PM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at LLY and PM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | LLY | PM |
|---|---|---|
| Company Name | Eli Lilly and Company | Philip Morris International Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Consumer Staples |
| GICS Industry | Pharmaceuticals | Tobacco |
| Market Capitalization | 865.16 billion USD | 241.39 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | June 1, 1972 | March 17, 2008 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of LLY and PM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | LLY | PM |
|---|---|---|
| 5-Day Price Return | 6.59% | 5.02% |
| 13-Week Price Return | 52.17% | -8.95% |
| 26-Week Price Return | 24.45% | -11.57% |
| 52-Week Price Return | 21.22% | 25.28% |
| Month-to-Date Return | 12.03% | 7.44% |
| Year-to-Date Return | 25.21% | 28.85% |
| 10-Day Avg. Volume | 5.22M | 6.36M |
| 3-Month Avg. Volume | 4.37M | 6.42M |
| 3-Month Volatility | 32.55% | 23.65% |
| Beta | 0.35 | 0.43 |
Profitability
Return on Equity (TTM)
LLY
102.26%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
LLY’s Return on Equity of 102.26% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
PM
575.44%
Tobacco Industry
- Max
- 49.48%
- Q3
- 49.48%
- Median
- 13.16%
- Q1
- 5.02%
- Min
- 4.04%
PM’s Return on Equity of 575.44% is exceptionally high, placing it well beyond the typical range for the Tobacco industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
LLY
30.99%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
A Net Profit Margin of 30.99% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
PM
21.57%
Tobacco Industry
- Max
- 21.36%
- Q3
- 16.88%
- Median
- 10.39%
- Q1
- 7.51%
- Min
- 4.74%
PM’s Net Profit Margin of 21.57% is exceptionally high, placing it well beyond the typical range for the Tobacco industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
Operating Profit Margin (TTM)
LLY
38.84%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
An Operating Profit Margin of 38.84% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
PM
36.95%
Tobacco Industry
- Max
- 18.53%
- Q3
- 15.03%
- Median
- 11.76%
- Q1
- 11.00%
- Min
- 6.94%
PM’s Operating Profit Margin of 36.95% is exceptionally high, placing it well above the typical range for the Tobacco industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
Profitability at a Glance
| Symbol | LLY | PM |
|---|---|---|
| Return on Equity (TTM) | 102.26% | 575.44% |
| Return on Assets (TTM) | 19.18% | 13.15% |
| Net Profit Margin (TTM) | 30.99% | 21.57% |
| Operating Profit Margin (TTM) | 38.84% | 36.95% |
| Gross Profit Margin (TTM) | 83.03% | 66.93% |
Financial Strength
Current Ratio (MRQ)
LLY
1.55
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
LLY’s Current Ratio of 1.55 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
PM
0.85
Tobacco Industry
- Max
- 3.37
- Q3
- 1.84
- Median
- 1.26
- Q1
- 0.79
- Min
- 0.39
PM’s Current Ratio of 0.85 aligns with the median group of the Tobacco industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
LLY
1.79
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
With a Debt-to-Equity Ratio of 1.79, LLY operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
PM
186.08
Tobacco Industry
- Max
- 2.19
- Q3
- 2.19
- Median
- 0.58
- Q1
- 0.07
- Min
- 0.01
With a Debt-to-Equity Ratio of 186.08, PM operates with exceptionally high leverage compared to the Tobacco industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
LLY
20.36
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
PM
11.67
Tobacco Industry
- Max
- 306.04
- Q3
- 126.21
- Median
- 9.35
- Q1
- 6.32
- Min
- -11.45
PM’s Interest Coverage Ratio of 11.67 is positioned comfortably within the norm for the Tobacco industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | LLY | PM |
|---|---|---|
| Current Ratio (MRQ) | 1.55 | 0.85 |
| Quick Ratio (MRQ) | 0.74 | 0.85 |
| Debt-to-Equity Ratio (MRQ) | 1.79 | 186.08 |
| Interest Coverage Ratio (TTM) | 20.36 | 11.67 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
LLY
0.60%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
LLY’s Dividend Yield of 0.60% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
PM
3.52%
Tobacco Industry
- Max
- 6.77%
- Q3
- 6.12%
- Median
- 5.06%
- Q1
- 3.83%
- Min
- 0.57%
PM’s Dividend Yield of 3.52% is in the lower quartile for the Tobacco industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
Dividend Payout Ratio (TTM)
LLY
28.28%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
LLY’s Dividend Payout Ratio of 28.28% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
PM
68.74%
Tobacco Industry
- Max
- 78.29%
- Q3
- 75.97%
- Median
- 64.37%
- Q1
- 50.14%
- Min
- 49.96%
PM’s Dividend Payout Ratio of 68.74% is within the typical range for the Tobacco industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | LLY | PM |
|---|---|---|
| Dividend Yield (TTM) | 0.60% | 3.52% |
| Dividend Payout Ratio (TTM) | 28.28% | 68.74% |
Valuation
Price-to-Earnings Ratio (TTM)
LLY
47.46
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
At 47.46, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
PM
27.80
Tobacco Industry
- Max
- 44.17
- Q3
- 36.23
- Median
- 27.79
- Q1
- 11.97
- Min
- 9.91
PM’s P/E Ratio of 27.80 is within the middle range for the Tobacco industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
LLY
14.71
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
With a P/S Ratio of 14.71, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
PM
6.00
Tobacco Industry
- Max
- 7.60
- Q3
- 5.15
- Median
- 2.97
- Q1
- 1.39
- Min
- 0.80
PM’s P/S Ratio of 6.00 is in the upper echelon for the Tobacco industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
LLY
30.35
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
At 30.35, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
PM
1,368.86
Tobacco Industry
- Max
- 4.76
- Q3
- 4.76
- Median
- 3.34
- Q1
- 1.97
- Min
- 1.05
At 1,368.86, PM’s P/B Ratio is at an extreme premium to the Tobacco industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | LLY | PM |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 47.46 | 27.80 |
| Price-to-Sales Ratio (TTM) | 14.71 | 6.00 |
| Price-to-Book Ratio (MRQ) | 30.35 | 1,368.86 |
| Price-to-Free Cash Flow Ratio (TTM) | 108.73 | 22.05 |